Literature DB >> 20536361

Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Rekha Singh1, Alan L Rothman, James Potts, Farshad Guirakhoo, Francis A Ennis, Sharone Green.   

Abstract

Flavivirus vaccines based on ChimeriVax technology contain the nonstructural genes of the yellow fever vaccine and the premembrane and envelope genes of heterologous flaviviruses, such as Japanese encephalitis and West Nile viruses. These chimeric vaccines induce both humoral and cell-mediated immunity. Mice were vaccinated with yellow fever, chimeric Japanese encephalitis virus (YF/JE), or chimeric West Nile virus (YF/WN) vaccines, followed by a secondary homologous or heterologous vaccination; the hierarchy and function of CD8(+) T cell responses to a variable envelope epitope were then analyzed and compared with those directed against a conserved immunodominant yellow fever virus NS3 epitope. Sequential vaccination with heterologous chimeric flaviviruses generated a broadly cross-reactive CD8(+) T cell response dependent on both the sequence of infecting viruses and epitope variant. The enhanced responses to variant epitopes after heterologous vaccination were not related to preexisting antibody or to higher virus titers. These results demonstrate that the sequence of vaccination affects the expansion of cross-reactive CD8(+) T cells after heterologous chimeric flavivirus challenge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536361      PMCID: PMC2903744          DOI: 10.1086/653486

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  CD8+ T cell effector mechanisms in resistance to infection.

Authors:  J T Harty; A R Tvinnereim; D W White
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model.

Authors:  C Rosette; G Werlen; M A Daniels; P O Holman; S M Alam; P J Travers; N R Gascoigne; E Palmer; S C Jameson
Journal:  Immunity       Date:  2001-07       Impact factor: 31.745

3.  Dengue immune response: low affinity, high febrility.

Authors:  Raymond M Welsh; Alan L Rothman
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

4.  Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.

Authors:  E Keogh; J Fikes; S Southwood; E Celis; R Chesnut; A Sette
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

5.  Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Authors:  Thomas P Monath; Karen McCarthy; Philip Bedford; Casey T Johnson; Richard Nichols; Sutee Yoksan; Ron Marchesani; Michael Knauber; Keith H Wells; Juan Arroyo; Farshad Guirakhoo
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

Review 6.  Viral hemorrhagic fevers of South America.

Authors:  Robert B Tesh
Journal:  Biomedica       Date:  2002-09       Impact factor: 0.935

7.  Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.

Authors:  A Trojan; M Witzens; J L Schultze; R H Vonderheide; S Harig; A M Krackhardt; R A Stahel; J G Gribben
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

8.  Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.

Authors:  Robbert G van der Most; Laurie E Harrington; Vicki Giuggio; Patryce L Mahar; Rafi Ahmed
Journal:  Virology       Date:  2002-04-25       Impact factor: 3.616

Review 9.  The global emergence/resurgence of arboviral diseases as public health problems.

Authors:  Duane J Gubler
Journal:  Arch Med Res       Date:  2002 Jul-Aug       Impact factor: 2.235

10.  A protective role for dengue virus-specific CD8+ T cells.

Authors:  Lauren E Yauch; Raphaël M Zellweger; Maya F Kotturi; Afrina Qutubuddin; John Sidney; Bjoern Peters; Tyler R Prestwood; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more
  8 in total

1.  A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.

Authors:  Jue Hou; Shuhui Wang; Manxue Jia; Dan Li; Ying Liu; Zhengpeng Li; Hong Zhu; Huifang Xu; Meiping Sun; Li Lu; Zhinan Zhou; Hong Peng; Qichen Zhang; Shihong Fu; Guodong Liang; Lena Yao; Xuesong Yu; Lindsay N Carpp; Yunda Huang; Julie McElrath; Steve Self; Yiming Shao
Journal:  J Immunol       Date:  2017-07-07       Impact factor: 5.422

2.  Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.

Authors:  Manijeh Mahdavi; Mehrnaz Keyhanfar; Abbas Jafarian; Hassan Mohabatkar; Mohammad Rabbani
Journal:  Tumour Biol       Date:  2014-08-21

3.  Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells.

Authors:  Wilfried A A Saron; Abhay P S Rathore; Lim Ting; Eng Eong Ooi; Jenny Low; Soman N Abraham; Ashley L St John
Journal:  Sci Adv       Date:  2018-07-04       Impact factor: 14.136

4.  NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.

Authors:  B Grubor-Bauk; D K Wijesundara; M Masavuli; P Abbink; R L Peterson; N A Prow; R A Larocca; Z A Mekonnen; A Shrestha; N S Eyre; M R Beard; J Gummow; J Carr; S A Robertson; J D Hayball; D H Barouch; E J Gowans
Journal:  Sci Adv       Date:  2019-12-11       Impact factor: 14.136

5.  Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice.

Authors:  Ji Ma; Robbert Boudewijns; Lorena Sanchez-Felipe; Niraj Mishra; Thomas Vercruysse; Dieudonné Buh Kum; Hendrik Jan Thibaut; Johan Neyts; Kai Dallmeier
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

6.  Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.

Authors:  Patrícia C C Neves; Juliana R Santos; Luciana N Tubarão; Myrna C Bonaldo; Ricardo Galler
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

Review 7.  Cross-Reactive Immunity Among Flaviviruses.

Authors:  Abhay P S Rathore; Ashley L St John
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

8.  Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein.

Authors:  Lennon Ramos Pereira; Rúbens Prince Dos Santos Alves; Natiely Silva Sales; Robert Andreata-Santos; Aléxia Adrianne Venceslau-Carvalho; Samuel Santos Pereira; Maria Fernanda Castro-Amarante; Mônica Josiane Rodrigues-Jesus; Marianna Teixeira de Pinho Favaro; Rosa Maria Chura-Chambi; Ligia Morganti; Luís Carlos de Souza Ferreira
Journal:  Front Med Technol       Date:  2020-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.